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Wiskott–Aldrich Syndrome (WAS) is a X-linked primary immunodeﬁciency disorder also marked by
a very high (up to 70%) incidence of autoimmunity. Wiskott–Aldrich Syndrome arises from muta-
tions in the Wiskott–Aldrich Syndrome protein (WASp), a cytoplasmic protein that links signaling
by cell surface receptors such as the T-cell receptor and integrins to actin polymerization. WASp pro-
motes the functions of multiple cell types that support immune responses, but also is important for
the function of regulatory T cells and in TCR-induced apoptosis, two negative mechanisms of
immune regulation that maintain peripheral immune tolerance. Here we review the nature of
immune defects and autoimmunity in WAS and WASp deﬁcient mice and discuss how this single
gene defect can simultaneously impair immune responses to pathogens and promote autoimmu-
nity. The myriad cellular immune defects found in WAS make this Mendelian syndrome an interest-
ing model for the study of more complex immune diseases that arise from the interplay of
environmental and multiple genetic risk factors.
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.The Wiskott–Aldrich Syndrome (WAS) is a X-linked primary
immunodeﬁciency disorder occurring with a frequency of between
1 and 10 per million males. WAS results from mutations in the
gene coding for the Wiskott–Aldrich Syndrome protein (WASp), a
key regulator of branched actin chain polymerization [1]. However,
the clinical manifestations of WAS are not limited to immunodeﬁ-
ciency, thrombocytopenia and eczema, the classically deﬁned trio
of symptoms in this syndrome. A remarkably high percentage of
WAS patients also develop autoimmunity. The protean clinical
manifestations of this single-gene disease likely arise from the
numerous cellular processes that rely on WASp to regulate
dynamic changes in the cytoskeleton in response to signal trans-
duction by a number of cell surface receptors. Here we will review
the mechanisms underlying WAS with particular attention to the
pathogenesis of autoimmunity in WAS and WASp-deﬁcient mice.
Understanding the aspects of immune system function which are
disrupted in a single gene disorder such as WAS can shed light
on signal transduction pathways which underlie generation of
effective immune responses as well as those involved in maintain-
ing immunological tolerance.on behalf of the Federation of Euro
.gov (R.M. Siegel).1. Wiskott–Aldrich Syndrome and the WASp protein
Mutations in the WASP gene coding for the Wiskott–Aldrich
Syndrome protein (WASp) were identiﬁed as the cause of most
cases of WAS in 1994 [2]. WASp is a 502 amino acid protein with
ﬁve functional domains: an N-terminal Drosophila-enabled/vaso-
dilator-stimulated phosphoprotein homology 1 (EVH1) domain,
a basic region, a GTPase-binding domain (GBD), a polyproline-rich
region (PRR) and a C-terminal verprolin homology/central region/
acidic region (VCA) domain [3,4] (Fig. 1). The major function of
WASp is to activate the Arp2/3 complex through its VCA domain
which results in the polymerization of branched actin ﬁlaments.
Regulated formation of branched actin ﬁlaments underlie forma-
tion of cellular structures such as lamellopodia, and functions in
cell migration, endocytosis, and vesicle trafﬁcking. Signals from
cell surface receptors activate WASp through the activating the
CDC42 GTPase. This GTPase binds WASP in its activated form,
and induces a conformational change in WASp that activates its
actin polymerizing activity. Because CDC42 can be rapidly acti-
vated and inactivated by various cellular signaling pathways, this
mechanism allows the tight control over actin polymerization/
depolymerization necessary for rapid cellular responses. Signals
acting through other domains of WASp can synergize with
CDC42 binding to optimize WASp activity. Other modifying sig-
nals that regulate WASp activity include Phosphatidylinositol
4,5-bisphosphate (PIP2) binding to the basic domain, WASppean Biochemical Societies.
Fig. 1. Wiskott–Aldrich Syndrome Protein domains and function The indicated
domains of WASp are shown schematically, with proteins and other molecules
binding WASp shown below the schematic, and functions shown above. EVH1/WH1
domain: enabled VASP (vasodilator-stimulated protein) homology 1)/WH1 (WASP
Homology (1). B: Basic Domain. GBD: GTPase Binding Domain. Proline Rich Domain
(PRD). The PRD of WASp has been reported to bind numerous Src Homology 3 (SH3)
domain containing proteins, including Btk, Hck, Fyn, Lyn, Itk, Nck, c-Src. Grb2, p85a,
PI-3K, PLC-g, PSTPIP1, PTP-PEST, proﬁlin and VASP [38,39]. PSTPIP1 binding has
been implicated in trafﬁcking of WASp to the immune synapse [15], and binding of
Fyn and PTP-PEST has been implicated in regulating tyrosine 291 phosphorylation
and the function of WASp in T cell activation [21]. VCA domain: Verprolin, coﬁlin,
acidic domain.
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SH3-domain containing proteins to the Proline Rich Domain
(PRD)[3] (Fig. 1).
The type of mutation in the WASP gene strongly inﬂuences the
clinical severity of Wiskott–Aldrich Syndrome [1,3]. Premature ter-
mination and deletion mutations inWASp that ablate expression of
Wiskott–Aldrich Syndrome protein usually result in severe, classi-
cal WAS. These patients present with neonatal thrombocytopenia
and dysfunctional platelets that can be accompanied by excessive
bleeding, eczema, and severe infections early in life. These compli-
cations can be fatal if not treated with bone marrow transplanta-
tion or gene therapy. Missense mutations in the WAS gene that
allow WASp protein expression with reduced function usually
result in phenotypically milder cases. Some of these cases are
limited to thrombocytopenia, termed X-linked thrombocytopenia
(XLT) that can be intermittent [1,5,6]. Interestingly, activating
mutations in WASp can result in a distinct clinical syndrome of
severe congenital x-linked neutropenia (XLN) [7].
The immune deﬁciencies in WAS result from effects on a
remarkably broad spectrum of cell types leading to defects in both
cellular and humoral immunity. IgG levels are generally normal,
but depressed IgM levels and elevated levels of IgA and IgE can oc-
cur. Patients with severe WAS have reduced responses to polysac-
charide antigens and class switching in response to protein
antigens [1]. Lymphocyte numbers tend to be normal at birth,
but then decline with age with lymphopenia below 1000 cells/
mm3 in about a quarter of patients [8]. Depressed T cell function
as measured by Delayed-Type Hypersensitivity responses and
mitogen-induced proliferation has been reported. In a number of
retrospective case studies, 40–72% of WAS patients have autoim-
munity. Autoimmunity associated with WAS manifested most
frequently by autoimmune hemolytic anemia, but other complica-
tions such vasculitis resembling Henoch–Schönlein purpura with
IgA nephropathy, uveitis and inﬂammatory bowel disease have
also been reported [9–11]. While many thought that autoimmunity
was more common in patients with complete WASp protein deﬁ-
ciency, recent reports show that patients with only the mild form
of X-linked thrombocytopenia have autoimmunity [5].
2. Cellular immune defects in WAS and WASp deﬁciency in mice
Investigation of WASp deﬁcient mice has uncovered a large
number of distinct defects in immune function in multiple celltypes that are similar to those seen in WAS patients (Fig. 2). WASp
deﬁcient mice have thrombocytopenia and lymphopenia similar to
WAS patients, but do not develop eczema, hematopoietic malig-
nancies or abnormal bleeding that can be seen in WAS [12,13].
One colony of WASp deﬁcient mice developed spontaneous colitis
[12] but in other facilities, colitis in these mice is mainly seen after
irradiation or other stresses, suggesting the involvement of envi-
ronmental factors. WASp deﬁcient T cells exhibit poor T cell prolif-
eration after mitogen or antigen stimulation that could be rescued
by addition of IL-2 [14,15]. This may stem from reduced efﬁciency
of immune synapse formation between T cells and APC, but WASp
also appears to independently regulate the capacity of T cells to
secrete effector cytokines [16].
Part of the reason WASp deﬁciency produces such varied and
often mild defects is that there may be partial redundancy with
other related proteins which promote actin polymerization termed
type I nucleation promoting factors (NPF), including N-WASp,
WAVE, WASH, WHAMM, and JMY proteins. Unlike WASp, whose
expression is restricted to hematopoietic cells, N-WASp is ubiqui-
tously expressed in all cells and, N-WASp deﬁciency results in
defective endocytosis, exocytosis, and hair-follicle cycling [17].
WASH mediates endosome trafﬁcking, but functions at different
times and in different vesicles than N-WASp. WAVE proteins medi-
ate cell motility and membrane rufﬂing, WHAMM mediates
ER-Golgi transport and Golgi organization, and JMY mediates cell
motility [18]. Although N-WASp deﬁciency is lethal in mice, the
redundancy of N-WASp and WASp in lymphocytes was investi-
gated by creating mice which WASp, N-WASp, or both proteins
were ablated speciﬁcally in T cells or in the lymphocytes of chime-
ras with RAG deﬁcient blastocysts [19]. Remarkably, no defects
were seen in cells deﬁcient only in N-WASp, indicating that
N-WASp may be redundant for many of functions of lymphocytes
that are affected by WASp. However when B and T cells were dou-
bly deﬁcient in WASp and N-WASp, lymphopenia and a block in
thymic development prior to the CD4+CD8+ double positive T cell
stage was seen. Thymocytes from these mice displayed reduced
proliferation and chemotactic responses to CCL12, a critical chemo-
kine positioning cells within the thymus [19]. Of note, colitis in
WASp/N-WASp doubly-deﬁcient mice was more severe than in
WASp deﬁcient mice, possibly because of the lymphopenia and
reduced numbers of (Treg) T cells present in the doubly deﬁcient
mice.
Expression of targeted mutations of WASp in T cells and in
transgenic and knock-in mice have helped to deﬁne the functions
of each domain of WASp and dissect their contribution to the clin-
ical manifestations of WAS (Fig. 1). Deletion of the EVH1 domain
reduces the ability of WASp to bind to WIP, which binds to and sta-
bilizes WASp [20]. Since the majority of WAS point mutations in
patients are at the N-terminal region of WASp, including many
within the EVH1 domain, WIP binding appears necessary in vivo
to stabilize WASp expression in vivo. In mice expressing WASp
missing the GBD, binding of Cdc42 is ablated as would be pre-
dicted, but T cells proliferate normally after activation, suggesting
that WASp acts in T cell activation independently of the GBD [21].
Instead, a key role of phosphorylation of Tyrosine at position 291 in
human (293 in mouse) in the GBD has been uncovered
[21,22].Mice expressing a mutant WASp protein which cannot be
phosphorylated at this position are similar to WASp deﬁcient ani-
mals, suggesting that phosphorylation of this tyrosine in the GBD is
required for WASp activation independently of CD42 binding.
Deletion of the Proline Rich Region (PRR) in WASp reduces forma-
tion of T cell:APC conjugates and actin polymerization suggesting
that the PRR is important for TCR signaling [15]. Interestingly, dele-
tion of the C terminal VCA domain in WASp results in defective
thymopoiesis, which is not seen in WASp deﬁcient mice [23], sug-
gesting that WASp lacking this C-terminal domain important for
Fig. 2. WASp affects multiple cellular processes in immunity. Green arrows represent processes with positive inﬂuence on immune responses and red arrows represent
processes that reduce immune responses through cytotoxicity or other regulatory mechanisms. Immune processes inﬂuenced byWASp are numbered in the ﬁgure with green
numbers denoting effects of WASp that enhance immune responses and red denoting effects of WASp which regulate immune responses. Speciﬁc functions of WASp are
numbered as follows: (1) WASp promotes dendritic cell (DC) podosome formation and migration [40], presentation of particulate antigens [41] and T-DC contacts in the
immune synapse in a DC intrinsic manner [42,43] (2) WASp in T cells can enhance the efﬁciency of immune synapse formation which contributes to T cell activation [14,15]
(3) WASp also promotes cytokine secretion which also contributes to T cell activation and effector function [16] (4) WASp promotes restimulation-induced cell death and
release of cytotoxic granules and FasL[24]. (5) WASp promotes B cell adhesion, migration, and germinal center formation [33] (6) WASp promotes T reg homeostasis, Treg
control of effector T cell proliferation and Treg killing of B cells [25,28,35]. (7) WASp promotes cytotoxicity of NK cells [37] (8) WASp may also promote uptake of apoptotic
blebs by macrophages [44], although we have not reproduced this defect in WASp deﬁcient macrophages [24].
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WASp and other NPF family proteins.
3. Autoimmunity in WASp deﬁciency: cellular and molecular
mechanisms
The study of autoimmunity inWASp deﬁcient mice may help in-
form our understanding of the pathogenesis of the autoimmune
manifestation in WAS patients. Other than colitis, autoimmunity
in WASp deﬁcient mice had not been studied until recently. We
and others have found that older WASp deﬁcient mice develop
anti-nuclear and anti-dsDNA antibodies at much higher rates than
isogenic controls with titers approaching those of other autoim-
mune-prone mouse strains such as MRL/lpr and NZB/NZWF1
[24,25]. In WASp deﬁcient mice on a 129SvEv background over six
months of age, we found circulating immune complexes, immune
complex deposition in the kidney, and mild nephritis resembling
the IgA nephropathy seen in some WAS patients [24]. Recently,
anti-platelet antibodies have been found in up to 40% of WASp
deﬁcient mice accompanied by evidence of increased platelet turn-
over [26].
Defective homeostasis and function of regulatory T cells (Treg)
may account for some of the observed autoimmunity seen inWASp
deﬁcient mice and WAS patients. While numbers of FoxP3(+) Tregs
are normal in the periphery and thymus of WASp deﬁcient mice, in
bone marrow chimera experiments in mice, WASp deﬁcient Treg
were out-competed by normal Treg, suggesting a cell-intrinsic role
for WASp in Treg survival. WASp deﬁcient Treg proliferated poorly
and failed to produce TGF-b when stimulated in vitro. These
defects could not be rescued by exogenous IL-2 [25,27]. WASp deﬁ-
cient Treg exhibited weaker suppression of normal T cell prolifer-
ation and had reduced ability to prevent colitis induced by naïve
T cells transferred into immunodeﬁcient hosts. Treg from WAS pa-
tients display similar abnormalities in activation and function
[27,28]. Why Treg are particularly affected by WASp deﬁciency is
not clear. Defective Treg homeostasis may stem from the depen-
dency of Treg on Interleukin-2 for survival, which may be limiting
in WASp deﬁciency. Functional defects in Treg may be related toknown T cell activation defects, or problems with secretion of cyto-
toxic granules by WASp deﬁcient Treg.
The ability of mature T cells to undergo programmed cell death
when restimulated through the TCR is also disrupted by WASp
deﬁciency and this may contribute to autoimmunity in WAS inde-
pendently of defects in Treg. Restimulation of activated T cells
through the TCR results in programmed cell death, mediated in
large part by autocrine stimulation of the TNF-family receptor
Fas by Fas Ligand (FasL) [29]. Humans and mice with genetic de-
fects in cell death induced by restimulation with antigen (Restim-
ulation-Induced Cell Death, or RICD), including those with defects
in Fas or Fas Ligand, produce autoantibodies and suffer from auto-
antibody mediated disease similar to the complications of WAS
[30]. Activated WASp deﬁcient T cells underwent signiﬁcantly re-
duced RICD compared to isogenic control cells. This occurred in T
cells from young mice even before the onset of autoantibody pro-
duction, suggesting that the TCR-induced apoptosis defect is an
intrinsic property of WASp deﬁcient cells [24].
Rather than stemming from a cell intrinsic defect in Fas signal-
ing, the mechanism of resistance to RICD in WASp deﬁciency ap-
pears to be related to production of Fas Ligand. WASp deﬁcient T
cells underwent normal programmed cell death when exposed to
exogenous FasL, but produced signiﬁcantly less FasL compared to
wild-type cells. FasL, like all other TNF family cytokines, is pro-
duced initially as a type II transmembrane protein. FasL can be
cleaved off the cell membrane by ADAM family metalloproteases
to produce soluble FasL [31], or secreted in a high-molecular
weight form believed to be derived from secretion of FasL anchored
in exosome-like secretory vesicles [31]. Fas-dependent apoptosis is
highly dependent on the oligomerization state of FasL, only mem-
brane-bound and vesicular FasL can induce apoptosis, whereas sol-
uble FasL does not, and can indeed antagonize apoptosis induced
by membrane-bound FasL. Reinforcing this dichotomy, mice in
which only soluble FasL are produced develop systemic autoimmu-
nity as severe as that in FasL deﬁcient mice [32]. Further analysis of
FasL secretion in WASp deﬁcient cells revealed normal surface
FasL, but reduced amounts of secreted FasL, both in soluble and
high-molecular weight form. Supernatants from restimulated
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plied to bystander Fas-sensitive tumor cells. Restimulated CD4+ T
cells also released less beta-hexosaminadase, suggesting a more
generalized defect in granule secretion in WASp deﬁcient T cells
restimulated CD4+ T cells [24]. Why WASp deﬁcient T cells pro-
duce less functional FasL is less clear, WASp-dependent cytoskele-
tal remodeling may be necessary for efﬁcient secretion of FasL and
potentially other molecules, or a step in TCR signaling important in
generating secreted vesicular FasL may depend onWASp. Taken to-
gether the data on defective RICD and FasL secretion in WASp deﬁ-
ciency provide a striking example of how a similar cell biological
defect in secretion of granule associated proteins can promote
immunodeﬁciency, through reduced secretion of effector cyto-
kines, and autoimmunity, through reduced secretion of negative
immune modulators such as FasL. This paradigm may apply to
other mutations affecting affect both positive and regulatory as-
pects of immunity.
Immune deﬁciency and autoantibody production in WASp deﬁ-
ciency likely has a B cell intrinsic component as well. WASp deﬁ-
cient mice have reduced germinal center formation and B cell
migration and proliferation defects [33]. In bone-marrow chimeras,
WASp deﬁciency impairs mature B cell survival and homeostasis in
a B cell intrinsic fashion [34]. Wasp deﬁcient mouse Treg are also
defective in killing of activated B cells, suggesting that autoantibod-
ies in WAS may arise because of failure to eliminate potentially
autoreactive B cells [35]. Cell-intrinsic defects in neutrophils, den-
dritic cells, NK cells and other cell types in the innate immune sys-
tem have also been reported in WAS patients or WASp deﬁcient
mice. [36,37] (Fig. 2). Collectively, these defects likely account for
the complex immune dysfunction seen in patients with WAS and
WASp deﬁcient mice.
Perhaps because of the redundancy of WASp with other mem-
bers of the NBD family of proteins regulating branched actin chain
formation, the defects in WASp deﬁciency tend to be partial, rather
than absolute, but the number of cell types affected may lead to the
high penetrance of immunodeﬁciency and autoimmunity in all but
those with the mildest molecular lesions in theWASP gene. Defects
in both positive and negative regulation of immune responses in
WAS lead to a situation of immune dysregulation akin to taking
ones feet off both the accelerator and the brake while driving, with
consequences for loss of control of immune responses. Because of
the pleiotropic effects of WASp on immune function, WAS resem-
bles complex autoimmune and immunodeﬁciency diseases that
stem from the interplay of multiple genetic and environmental risk
factors. As such, the study of WAS and WASp deﬁcient mice is
likely to continue to yield insights into the pathogenesis of immu-
nodeﬁciency and autoimmunity with implications beyond the
relatively small number of patients afﬂicted with this syndrome.
Acknowledgements
We would like to thank Nikolay Nikolov for critical reading of
the manuscript. This work was supported by the intramural
research program of the National Institute of Arthritis and Muscu-
loskeletal and Skin Diseases (NIAMS), and an F31 training grant to
S.Y.C. from NIAMS.
References
[1] Ochs, H. and Thrasher, A. (2006) The Wiskott–Aldrich syndrome. Journal of
Allergy and Clinical Immunology 117, 725–738, doi:10.1016/
j.jaci.2006.02.005.
[2] Derry, J.M.J., Ochs, H.D. and Francke, U. (1994) Isolation of a novel gene
mutated in Wiskott–Aldrich syndrome. Cell 78, 635–644.
[3] Burns, S. (2004) Mechanisms of WASp-mediated hematologic and
immunologic disease. Blood 104, 3454–3462, doi:10.1182/blood-2004-04-
1678.[4] Thrasher, A.J. and Burns, S.O. (2010) WASP: a key immunological multitasker.
Nat. Rev. Immunol. 10, 182–192, doi:10.1038/nri2724.
[5] Imai, K., Morio, T., Zhu, Y., Jin, Y., Itoh, S., Kajiwara, M., Yata, J., Mizutani, S.,
Ochs, H.D. and Nonoyama, S. (2004) Clinical course of patients with WASP
gene mutations. Blood 103, 456–464.
[6] Albert, M.H., Bittner, T.C., Nonoyama, S., Notarangelo, L.D., Burns, S., Imai, K.,
Espanol, T., Fasth, A., Pellier, I., Strauss, G., et al. (2010) X-linked
thrombocytopenia (XLT) due to WAS mutations: clinical characteristics,
long-term outcome, and treatment options. Blood 115, 3231–3238.
[7] Devriendt, K., Kim, A.S., Mathijs, G., Frints, S.G., Schwartz, M., Van Den Oord,
J.J., Verhoef, G.E., Boogaerts, M.A., Fryns, J.P., You, D., et al. (2001)
Constitutively activating mutation in WASP causes X-linked severe
congenital neutropenia. Nat. Genet. 27, 313–317, doi:10.1038/85886.
[8] Sullivan, K.E., Mullen, C.A., Blaese, R.M. and Winkelstein, J.A. (1994) A
multiinstitutional survey of the Wiskott–Aldrich syndrome. J. Pediatr. 125,
876–885.
[9] Akman, I.O., Ostrov, B.E. and Neudorf, S. (1998) Autoimmune manifestations of
the Wiskott–Aldrich syndrome. Semin. Arthritis Rheum. 27, 218–225.
[10] Schurman, S.H. and Candotti, F. (2003) Autoimmunity in Wiskott–Aldrich
syndrome. Curr. Opin. Rheumatol. 15, 446–453.
[11] Dupuis-Girod, S., Medioni, J., Haddad, E., Quartier, P., Cavazzana-Calvo, M., Le
Deist, F., De Saint Basile, G., Delaunay, J., Schwarz, K., Casanova, J.-L., et al.
(2003) Autoimmunity in Wiskott–Aldrich Syndrome: risk factors, clinical
features, and outcome in a single-center cohort of 55 patients. Pediatrics 111,
e622–e627, doi:10.1542/peds.111.5.e622.
[12] Snapper, S.B., Rosen, F.S., Mizoguchi, E., Cohen, P., Khan, W., Liu, C.H.,
Hagemann, T.L., Kwan, S.P., Ferrini, R., Davidson, L., et al. (1998) Wiskott–
Aldrich syndrome protein-deﬁcient mice reveal a role for WASP in T but not B
cell activation. Immunity 9, 81–91.
[13] Zhang, J., Shehabeldin, A., da Cruz, L.A., Butler, J., Somani, A.K., McGavin, M.,
Kozieradzki, I., dos Santos, A.O., Nagy, A., Grinstein, S., et al. (1999) Antigen
receptor-induced activation and cytoskeletal rearrangement are impaired in
Wiskott–Aldrich syndrome protein-deﬁcient lymphocytes. J. Exp. Med. 190,
1329–1342.
[14] Cannon, J.L. and Burkhardt, J.K. (2004) Differential roles for Wiskott–Aldrich
syndrome protein in immune synapse formation and IL-2 production. J.
Immunol. 173, 1658–1662.
[15] Badour, K., Zhang, J., Shi, F., McGavin, M.K., Rampersad, V., Hardy, L.A., Field, D.
and Siminovitch, K.A. (2003) The Wiskott–Aldrich syndrome protein acts
downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote
formation of the immunological synapse. Immunity 18, 141–154.
[16] Morales-Tirado, V., Johannson, S., Hanson, E., Howell, A., Zhang, J., Siminovitch,
K.A. and Fowell, D.J. (2004) Cutting edge: selective requirement for the
Wiskott–Aldrich syndrome protein in cytokine, but not chemokine, secretion
by CD4+ T cells. J. Immunol. 173, 726–730.
[17] Derivery, E. and Gautreau, A. (2010) Generation of branched actin networks:
assembly and regulation of the N-WASP and WAVE molecular machines.
BioEssays 32, 119–131, doi:10.1002/bies.200900123.
[18] Rottner, K., Hanisch, J. and Campellone, K.G. (2010) WASH, WHAMM and
JMY: regulation of Arp2/3 complex and beyond. Trends Cell Biol. 20, 650–
661.
[19] Cotta-de-Almeida, V., Westerberg, L., Maillard, M.H., Onaldi, D., Wachtel, H.,
Meelu, P., Chung, U.I., Xavier, R., Alt, F.W. and Snapper, S.B. (2007) Wiskott–
Aldrich syndrome protein (WASP) and N-WASP are critical for T cell
development. Proc. Natl. Acad. Sci. U.S.A. 104, 15424–15429.
[20] Konno, A., Kirby, M., Anderson, S.A., Schwartzberg, P.L. and Candotti, F. (2007)
The expression of Wiskott–Aldrich syndrome protein (WASP) is dependent on
WASP-interacting protein (WIP). Int. Immunol. 19, 185–192. doi: dxl135 [pii]
10.1093/intimm/dxl135.
[21] Badour, K., Zhang, J., Shi, F., Leng, Y., Collins, M. and Siminovitch, K.A. (2004)
Fyn and PTP-PEST-mediated regulation of Wiskott–Aldrich syndrome protein
(WASp) tyrosine phosphorylation is required for coupling T cell antigen
receptor engagement to WASp effector function and T cell activation. J. Exp.
Med. 199, 99–112.
[22] Blundell, M.P., Bouma, G., Metelo, J., Worth, A., Calle, Y., Cowell, L.A.,
Westerberg, L.S., Moulding, D.A., Mirando, S., Kinnon, C., et al. (2009)
Phosphorylation of WASp is a key regulator of activity and stability in vivo.
Proc. Natl. Acad. Sci. U.S.A. 106, 15738–15743.
[23] Zhang, J., Shi, F., Badour, K., Deng, Y., McGavin, M.K. and Siminovitch, K.A.
(2002) WASp verprolin homology, coﬁlin homology, and acidic region
domain-mediated actin polymerization is required for T cell development.
Proc. Natl. Acad. Sci. U.S.A. 99, 2240–2245.
[24] Nikolov, N.P., Shimizu, M., Cleland, S., Bailey, D., Aoki, J., Strom, T.,
Schwartzberg, P.L., Candotti, F. and Siegel, R.M. (2010) Systemic
autoimmunity and defective Fas ligand secretion in the absence of the
Wiskott–Aldrich syndrome protein. Blood 116, 740–747.
[25] Humblet-Baron, S., Sather, B., Anover, S., Becker-Herman, S., Kasprowicz, D.J.,
Khim, S., Nguyen, T., Hudkins-Loya, K., Alpers, C.E., Ziegler, S.F., et al. (2007)
Wiskott–Aldrich syndrome protein is required for regulatory T cell
homeostasis. J. Clin. Invest. 117, 407–418.
[26] Marathe, B.M., Prislovsky, A., Astrakhan, A., Rawlings, D.J., Wan, J.Y. and Strom,
T.S. (2009) Antiplatelet antibodies in WASP(-) mice correlate with evidence of
increased in vivo platelet consumption. Exp. Hematol. 37, 1353–1363,
doi:10.1016/j.exphem.2009.08.007.
[27] Marangoni, F., Trifari, S., Scaramuzza, S., Panaroni, C., Martino, S., Notarangelo,
L.D., Baz, Z., Metin, A., Cattaneo, F., Villa, A., et al. (2007) WASP regulates
3714 S.Y. Cleland, R.M. Siegel / FEBS Letters 585 (2011) 3710–3714suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural
regulatory T cells. J. Exp. Med. 204, 369–380.
[28] Adriani, M., Aoki, J., Horai, R., Thornton, A., Konno, A., Kirby, M., Anderson, S.,
Siegel, R., Candotti, F. and Schwartzberg, P. (2007) Impaired in vitro regulatory
T cell function associated with Wiskott–Aldrich syndrome. Clin. Immunol.
124, 41–48.
[29] Siegel, R.M., Chan, F.K., Chun, H.J. and Lenardo, M.J. (2000) The multifaceted
role of Fas signaling in immune cell homeostasis and autoimmunity. Nat.
Immunol. 1, 469–474.
[30] Straus, S.E., Sneller, M., Lenardo, M.J., Puck, J.M. and Strober, W. (1999) An
inherited disorder of lymphocyte apoptosis: the autoimmune
lymphoproliferative syndrome. Ann. Intern. Med. 130, 591–601.
[31] Kirkin, V., Cahuzac, N., Guardiola-Serrano, F., Huault, S., Luckerath, K.,
Friedmann, E., Novac, N., Wels, W.S., Martoglio, B., Hueber, A.O., et al. (2007)
The Fas ligand intracellular domain is released by ADAM10 and SPPL2a
cleavage in T-cells. Cell Death Differ 14, 1678–1687. Doi: 4402175 [pii]
10.1038/sj.cdd.4402175.
[32] O’ Reilly, L.A., Tai, L., Lee, L., Kruse, E.A., Grabow, S., Fairlie, W.D., Haynes, N.M.,
Tarlinton, D.M., Zhang, J.G., Belz, G.T., et al. (2009) Membrane-bound Fas
ligand only is essential for Fas-induced apoptosis. Nature 461, 659–663.
[33] Westerberg, L., Larsson, M., Hardy, S.J., Fernández, C., Thrasher, A. and
Severinson, E. (2005) Wiskott–Aldrich syndrome protein deﬁciency leads to
reduced B-cell adhesion, migration, and homing, and a delayed humoral
immune response. Blood 105, 1144–1152, doi:10.1182/blood-2004-03-1003.
[34] Meyer-Bahlburg, A., Becker-Herman, S., Humblet-Baron, S., Khim, S., Weber,
M., Bouma, G., Thrasher, A.J., Batista, F.D. and Rawlings, D.J. (2008) Wiskott–
Aldrich syndrome protein deﬁciency in B cells results in impaired peripheral
homeostasis. Blood 112, 4158–4169. doi: blood-2008-02-140814.
[35] Adriani, M., Jones, K.A., Uchiyama, T., Kirby, M.R., Silvin, C., Anderson, S.M. and
Candotti, F. (2011) Defective inhibition of B-cell proliferation by Wiskott–
Aldrich syndrome protein-deﬁcient regulatory T cells. Blood 117. 6608-6611
10.1182/blood-2010-12-322834.
[36] Bosticardo, M., Marangoni, F., Aiuti, A., Villa, A. and Grazia Roncarolo, M.
(2009) Recent advances in understanding the pathophysiology of Wiskott–
Aldrich syndrome. Blood 113, 6288–6295. doi: blood-2008-12-115253.[37] Orange, J.S., Ramesh, N., Remold-O’Donnell, E., Sasahara, Y., Koopman, L.,
Byrne, M., Bonilla, F.A., Rosen, F.S., Geha, R.S. and Strominger, J.L. (2002)
Wiskott–Aldrich syndrome protein is required for NK cell cytotoxicity and
colocalizes with actin to NK cell-activating immunologic synapses. Proc. Natl.
Acad. Sci. U.S.A. 99, 11351–11356.
[38] Scott, M.P., Zappacosta, F., Kim, E.Y., Annan, R.S. and Miller, W.T. (2002)
Identiﬁcation of novel SH3 domain ligands for the Src family kinase Hck.
Wiskott–Aldrich syndrome protein (WASP), WASP-interacting protein (WIP),
and ELMO1. J. Biol. Chem. 277, 28238–28246.
[39] Castellano, F., Le Clainche, C., Patin, D., Carlier, M.F. and Chavrier, P. (2001) A
WASp-VASP complex regulates actin polymerization at the plasma
membrane. EMBO J. 20, 5603–5614.
[40] Dehring, D.A., Clarke, F., Ricart, B.G., Huang, Y., Gomez, T.S., Williamson, E.K.,
Hammer, D.A., Billadeau, D.D., Argon, Y. and Burkhardt, J.K. (2011)
Hematopoietic lineage cell-speciﬁc protein 1 functions in concert with the
Wiskott–Aldrich syndrome protein to promote podosome array organization
and chemotaxis in dendritic cells. J. Immunol. 186, 4805–4818.
[41] Westerberg, L., Wallin, R.P.A., Greicius, G., Ljunggren, H.-G. and Severinson, E.
(2003) Efﬁcient antigen presentation of soluble, but not particulate, antigen in
the absence of Wiskott–Aldrich syndrome protein. Immunology 109, 384–
391.
[42] Bouma, G., Mendoza-Naranjo, A., Blundell, M.P., de Falco, E., Parsley, K.L.,
Burns, S.O. and Thrasher, A.J. (2011) Cytoskeletal remodeling mediated by
WASp in dendritic cells is necessary for normal immune synapse formation
and T cell priming. Blood 118, 2492–2501.
[43] Pulecio, J., Tagliani, E., Scholer, A., Prete, F., Fetler, L., Burrone, O.R. and
Benvenuti, F. (2008) Expression of Wiskott–Aldrich syndrome protein in
dendritic cells regulates synapse formation and activation of naive CD8+ T
cells. J Immunol 181, 1135–1142.
[44] Leverrier, Y., Lorenzi, R., Blundell, M.P., Brickell, P., Kinnon, C., Ridley, A.J. and
Thrasher, A.J. (2001) Cutting edge: the Wiskott–Aldrich syndrome protein is
required for efﬁcient phagocytosis of apoptotic cells. J. Immunol. 166, 4831–
4834.
